Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
November 2020
-
Media Release
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other… -
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or… -
Predictive analytics could bring medicines to patients faster
Novartis researchers are using data to accelerate drug development.
-
Featured News
Achieving 100% renewable electricity
Five virtual power purchase agreements with three developers expected to add more than 275 megawatts of clean power to the electrical grid.
-
Media Release
Novartis set to achieve 100% renewable electricity in its European operations
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas… -
Making Possible: Stepping toward a future with cell and gene therapy
These stories offer a glimpse into the lives of people touched by a new era of medicine.
-
Featured News
Leading performance in sustainability
Novartis included in Dow Jones Sustainability World Index, with industry-leading performance in environmental and social reporting and human capital.
-
Media Release
Results from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis… -
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female… -
Featured News
Study suggests there may be two stages of fatal lung disease in COVID-19
NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.
-
Media Release
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical… -
Media Release
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first…
Pagination
- ‹ Previous page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- …
- 154
- › Next page
Test disclaimer...!!!